12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Other News

Gilead infectious news

Gilead said it received notice from the Chinese Patent Review Board late last month that a patent covering the company's HIV and HBV drug Viread tenofovir disoproxil fumarate has been invalidated in China. Gilead said there is an additional patent still...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >